Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A non-interventional, observational post-marketing registry of Vidaza (subcutaneous azacitidine) in patients with intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia with 20-30 % blasts and multi-lineage dysplasia in China

Trial Profile

A non-interventional, observational post-marketing registry of Vidaza (subcutaneous azacitidine) in patients with intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia with 20-30 % blasts and multi-lineage dysplasia in China

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2018

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top